Atomo Diagnostics Limited (ASX:AT1)


right-arrow Created with Sketch. -0.01 (-3.92%)
MCAP $144.9M
Last trade 16.10pm 19/01/2022 20mins delayed

Latest Announcements

30/12/2021 Price SensitivePSAT1Atomo Diagnostics Limited
10/12/2021AT1Atomo Diagnostics Limited
09/12/2021AT1Atomo Diagnostics Limited
26/11/2021AT1Atomo Diagnostics Limited
25/11/2021AT1Atomo Diagnostics Limited
10/11/2021AT1Atomo Diagnostics Limited
08/11/2021AT1Atomo Diagnostics Limited
08/11/2021AT1Atomo Diagnostics Limited

Company Overview

Atomo Diagnostics Ltd is an Australia-based medical device company. The Company is engaged in the development and sale of medical devices. Its AtomoRapid is offering rapid diagnostic test (RDT) platform, which provides devices to the global diagnostic market. Its RDT device platforms include Galileo, Pascal, Losev, Newton, Franklin and Elion. It also offers blood-based rapid diagnostic test (RDT) for screening for human immunodeficiency virus (HIV). Its RDT platform includes various features, such as integrated lancelet, blood collection, buffer delivery and digital display. It is also engaged in sales of Atomo branded COVID-19 rapid antibody and antigen tests in Australia.

AT1 in the news

Following recent trading activity, Atomo Diagnostics (AT1) has hit back at a…
Atomo Diagnostics (AT1) receives approval to supply its HIV Self-Test to a…
Atomo Diagnostics (AT1) and Access Bio are restructuring their commercial relationship to…
Atomo Diagnostics (AT1) is granted FDA clearance for its COVID-19 antibody testThe…

Search Previous Announcements